Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Quick Read

Tuesday's 'buy the dip' rally failed again, leaving the Nasdaq down 1% and S&P 500 lower, while bond yields pulled back from key resistance levels. Nike (NKE) was cut to Sector Perform at RBC with a $50 target, while STM was upgraded to Buy at Bank of America targeting $100. Oil dropped 3% as Iran peace optimism and increased Strait of Hormuz traffic drove selling, offering pump relief during the summer driving season. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bill Holdings didn't make the cut. Grab the names FREE today.

Pre-Market Stock Futures:

Futures are trading lower after the stock market tried to take a cue from Monday's action, and things didn't work out quite as well on Tuesday. Once again, the market gapped open higher as the "Buy the dip" legions came in to ride what they thought would be another wave higher, only to once again see the gains reversed. This time, Monday's pattern repeated, but the damage was greater: two of the four major indices closed lower, with the Dow Jones Industrial Average, which was the only index to close lower on Monday, finishing the session higher at 50,871, up 0.17%. The small-cap-heavy Russell 2000 closed the day at 2,864, up 0.32%. The Nasdaq finished the day down 0.97% at 25,678, while the S&P 500 was last seen down 0.26% at 7,386.

Treasury Bonds:

Yields were down across the Treasury curve, as every time the long end gets over the 5% levels, and the 10-year trades above 4.50%, the buyers return. Part of this is a yield play, but another big factor is adding some insurance, and many see an inevitable big decline coming our way. Either way, when the dust settled on Tuesday, the 30-year-long bond closed the day at 5.01%, while the benchmark 10-year note was last seen at 4.53%. Today's report on the Consumer Price Index for May and Thursday's Producer Price Index print could shape how the bond market trades for the rest of the second quarter.

Oil and Gas:

Oil prices were down across the board on Tuesday, as hopes for an end to the war with Iran surged on positive comments from the president, plus reports indicating that traffic in the Strait of Hormuz has increased, all of which added to the selling pressure, which Americans are cheering as the busy summer driving season is underway. Brent Crude closed the day at $91.65, down 2.75%, while West Texas Intermediate was last seen at $88.51, down 3.06%. The final trade for Natural Gas was reported at $3.14, down 3.o2%.

Gold:

The precious metals had a tough day, as trading remained range-bound for both Gold and Silver. This comes as Paul Wong, Sprott's market strategist, reminded investors that rising debt and inflation will remain the wind in the sails of the precious metals complex, which, as we have noted, has traded range-bound since late February. Gold closed Tuesday's session at $4,259, down 1.61%, while the last trade for Silver was reported at $65.21, down a whopping 4.08%.

Story Continues

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bill Holdings didn't make the cut. Grab the names FREE today.

Crypto:

Cryptocurrency markets declined on Tuesday, with Bitcoin trading near $62,500 after posting a roughly 1% loss over the past 24 hours. The broader digital asset market stayed under selling pressure as investors digested ongoing ETF outflows. Mid-week trading showed disappointing momentum, with crypto largely decoupling from a global rally in risk assets, which has run into a wall over the last two days. Although geopolitical tensions appeared to ease, concerns lingered about the prolonged streak of outflows from U.S. spot Bitcoin ETFs. At 8 AM EDT, Bitcoin traded at $62,030, while Ethereum traded at $1,659.

24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock.

Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Wednesday, June 10, 2026.

Upgrades:

Cava Group (NYSE: CAVA) was upgraded to Buy from Neutral at UBS, which bumped the target price for the stock to $90 from $85. Entergy(NYSE: ETR) was upgraded to Outperform from In Line at Evercore ISI, which raised the target price for the utility giant to $121 from $115. GlobalFoundries (NASDAQ: GFS) was upgraded to Buy from Neutral at Arete, without a target price. Pfizer (NYSE: PFE) was upgraded to Sector Perform from Underperform at RBC Capital, with a $25 target price. STMicroelectronics (NYSE: STM) was raised to Buy from Neutral at Bank of America, which raised the target price for the shares to $100 from $83.

Downgrades:

BILL Holdings (NYSE: BILL) was cut to Hold from Buy at Truist, which dropped the target price for the stock to $35 from $45 Hess Midstream (NYSE: HESM) was cut to Underweight from Equal Weight at Morgan Stanley, which has a $38 target price. Nike (NYSE: NKE) was downgraded to Sector Perform from Outperform at RBC Capital, which cut the target price for the sports apparel and shoe giant to $50 from $70. Nuvalent (NASDAQ: NUVL) was downgraded to Hold from Buy at TD Cowen, which dropped the target price for the share to $124 from $140. Taylor Morrison(NYSE: TMHC) was downgraded to Peer Perform from Outperform at Wolfe Research, with a $72.50 target price. That is the amount Berkshire Hathaway is paying to acquire the company.

Initiations:

3M Company (NYSE: MMM) was initiated with an Underperform rating at Bernstein, with a $131 target price. HoneywellInternational (NYSE: HON) was started with a Market Perform rating at Berstein, with a $233 target price. Power Integrations (NASDAQ: POWI) was started with a Buy rating at Needham, with a $90 target price objective. SharkNinja (NYSE: SN) was initiated with an Overweight rating at Piper Sandler, with a $150 target price. Vertiv Holdings (NYSE: VRT) was started with an Outperform rating at Bernstein, and has a $416 target price for the stock.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bill Holdings didn't make the cut. Grab the names FREE today.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

GSK (LSE:GSK) has agreed to acquire US biotech Nuvalent in a deal valued at US$10.6b. The transaction would add two late stage tyrosine kinase inhibitors for non small cell lung cancer to GSK's oncology portfolio. Both therapies are under regulatory review with anticipated near term launches.

GSK is a global pharmaceuticals company with a growing focus on specialty medicines, and this deal places oncology more clearly at the center of that effort. By adding Nuvalent's late stage lung cancer candidates, GSK is expanding beyond areas such as its hepatitis B franchise and broadening the mix of assets in its late stage pipeline. For investors, this is a sizable move that sits alongside existing vaccines and specialty drug lines.

Management has indicated that the Nuvalent acquisition is expected to contribute to revenue from 2027, which highlights the time horizon involved. The deal also suggests that GSK is prepared to deploy significant capital into late stage, high impact therapies, which may influence how investors think about its future earnings mix and risk profile within oncology and specialty medicines.

Stay updated on the most important news stories for GSK by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on GSK.LSE:GSK Earnings & Revenue Growth as at Jun 2026

We've flagged 3 risks for GSK. See which could impact your investment.

The Nuvalent deal points to GSK leaning harder into oncology as a second pillar alongside vaccines and infectious disease. By paying US$10.6b and offering a 40% premium in cash, GSK is effectively swapping balance sheet flexibility for late-stage lung cancer assets that already have US Food and Drug Administration target decision dates in 2026. For you as an investor, that means a clearer line of sight to potential product launches compared with earlier-stage acquisitions. Management has also said the acquisition is expected to start contributing to revenue from 2027, which fits with comments that Nuvalent will be accretive to core operating profit before earnings per share, where there is expected to be low single digit dilution until 2028. In the context of earlier partnerships in hepatitis B and liver disease, this move suggests GSK is comfortable using both collaborations and large acquisitions to fill pipeline gaps, particularly in cancer where peers such as AstraZeneca, Roche and Bristol Myers Squibb are active.

Story Continues

How This Fits Into The GSK Narrative

This acquisition supports the existing view that GSK is leaning into specialty medicines, since late-stage lung cancer therapies sit squarely in the oncology and high value biologic segment highlighted in the narrative. The sizeable cash and debt-funded consideration could challenge assumptions around future free cash flow and net debt in the narrative, especially as GSK also faces legal and pricing pressures. The specific focus on tyrosine kinase inhibitors for non small cell lung cancer and Nuvalent's preclinical portfolio is not fully captured in the broader discussion of oncology momentum that centers on Jemperli and other existing assets.

Knowing what a company is worth starts with understanding its story.Check out one of the top narratives in the Simply Wall St Community for GSK to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

⚠️ GSK is taking on low single digit core earnings per share dilution until 2028 from the Nuvalent deal, so there is execution risk if the acquired drugs or earlier pipeline do not progress as expected. ⚠️ Lung cancer is a crowded field with large competitors such as AstraZeneca, Merck and Roche, so pricing, reimbursement and differentiation for zidesamtinib, neladalkib and the third asset will be important. 🎁 The two lead Nuvalent therapies already have Breakthrough Therapy and Orphan Drug designations and US FDA target decision dates in 2026, which gives GSK potential near term additions to its oncology portfolio. 🎁 Adding three lung cancer products in advanced development complements GSK's existing oncology drugs and may help diversify future revenue sources across more tumor types and mechanisms.

What To Watch Going Forward

From here, keep an eye on the tender offer progress, the timing of deal closing and any updates from the planned M&A call. Once the acquisition completes, the next milestones will be the US FDA decisions for zidesamtinib and neladalkib, any regulatory feedback in other regions, and how GSK positions these therapies against established lung cancer regimens. It is also worth tracking management commentary on integration costs, use of debt facilities and how Nuvalent fits alongside existing oncology assets in terms of commercial focus and capital allocation priorities.

To ensure you're always in the loop on how the latest news impacts the investment narrative for GSK, head to the community page for GSK to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GSK.L.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Nach starken Gewinnen im letzten Jahr unterperformen Biotech-Aktien gegenüber dem Vorjahr, obwohl die M&A-Aktivität auf einem Rekordniveau liegt. Die Industrieanzeige State Street SPDR S&P Biotech ETF (XBI) hat sich nur um etwa 7% entwickelt, während der S&P 500 (SP500) um etwa 8% zulegt. Der M&A-Markt ist jedoch auf einem Höhepunkt und könnte mit 482 Deals im Wert von 254 Mrd. US-Dollar einen neuen Rekord erreichen. Zwei große Pharmaunternehmen haben in den letzten Tagen jeweils eine Milliarden-Transaktion abgeschlossen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der britische Pharma-Konzern GSK plc hat eine endgültige Vereinbarung geschlossen, um den Bostoner klinischen Entwickler Nuvalent, Inc. für 10,6 Milliarden Dollar in bar zu übernehmen. Die Transaktion stellt den zweitgrößten Biopharma-Übernahme des Jahres dar und bietet GSK einen sofortigen, hohen Wert im Zielmarkt für nicht kleine Zell-Lungenkrebs. Der Deal umfasst drei Produktlinien, darunter zwei spät-stufige, potenziell beste-in-Klasse-Tyrosinkinase-Inhibitoren unter Prioritätsprüfung durch die FDA, mit regulatorischen Genehmigungsentscheidungen bis zum Ende des Jahres geplant.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

(Bloomberg) -- GSK Plc agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that's developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise.

Most Read from Bloomberg

House Republican Says Hegseth's D-Day Remarks 'Inappropriate' LA Mayor Race Flips as Socialist Beats Reality TV Star Pratt Trump Says He, Not Congress, Is in Charge of Kennedy Center in Reversal Trump's $100,000 H-1B Visa Application Fee Rejected by Judge Chip Stocks Rally in AI Trade Revival After Plunge: Markets Wrap

GSK will pay $124 a share in cash for Nuvalent, according to a statement Tuesday, a 40% premium over the Cambridge, Massachusetts-based company's closing share price on Monday. It marks a significant expansion of GSK's cancer portfolio, which has been slowly growing since the British drugmaker returned to the disease space in 2019, as well as the first major acquisition for Chief Executive Officer Luke Miels.

Since taking over at the start of this year, Miels has been working to revitalize GSK, which doesn't have a history of risk-taking and has long struggled to allay investors' fears about the drugs it has in development.

GSK shares fell as much as 3% in early trading in London. The stock is up by around 23% over the past 12 months.

Nuvalent designs precisely-targeted therapies for oncology patients including lung cancer. Its shares have declined by 12% this year, giving it a market value of almost $7 billion.

Two of the medicines GSK is acquiring are in late-stage trials, with the US Food and Drug Administration expected to decide on regulatory approval later this year. Both could be blockbuster medicines if approved, GSK said.

The Nuvalent deal won't impact GSK's guidance for the year, and it's expected to contribute to revenue growth from 2027, according to the statement.

The two leading drugs from Nuvalent treat non-small-cell lung cancer patients that have specific mutations. These mutations usually affect people who didn't smoke.

The fortunes of GSK and rival British drugmaker AstraZeneca Plc diverged in 2014 as Astra CEO Pascal Soriot worked to make the company a cancer drug powerhouse.

GSK meanwhile divested its oncology portfolio in an asset swap with Novartis in 2014. Miels, a protégé of Soriot, left Astra acrimoniously, with the company suing him in 2017, alleging he was in violation of his employment agreement. The two companies settled, with Miels joining GSK later that year.

Story Continues

Well-liked by investors, the pick of Australian Miels to succeed Emma Walmsley as CEO was seen as a move that could rejuvenate GSK. The drugmaker, known for its vaccines, has focused on immunology and HIV as vaccine sales have slowed.

In January, GSK agreed on a $2.2 billion deal to buy US biotech Rapt Therapeutics, which develops treatments for inflammatory and immunologic diseases. The firm secured a pulmonary hypertension drug in another transaction.

The Nuvalent purchase is expected to be completed by the third quarter, pending regulatory approvals. The transaction will be funded mainly through new and existing debt facilities plus cash and won't affect GSK's credit rating, the company said.

--With assistance from Michelle F. Davis.

(Updates with shares in fourth paragraph.)

Most Read from Bloomberg Businessweek

Chinese Diners Will Wait Five Hours for This Conveyor-Belt Sushi SpaceX IPO Forces Investors to Bet on Musk's Entangled AI Empire Men in Blazers Is Coming to Take Over the World Cup Where's the Global Economic Meltdown? What Trump Delivered for Amazon

©2026 Bloomberg L.P.

View Comments